This category covers biotechnology and pharmaceutical companies developing therapies targeting copper homeostasis, zinc/copper transport, metalloprotein modulation, and related metal transport mechanisms in Alzheimer's disease. These approaches address the disrupted copper and zinc balance in the AD brain, which contributes to amyloid-beta aggregation, oxidative stress, synaptic dysfunction, and neuroinflammation.
Copper and zinc homeostasis is among the earliest detectable abnormalities in Alzheimer's disease, often preceding clinical symptoms by decades. The brain's copper and zinc balance is disrupted through multiple mechanisms: altered transport proteins (ATP7A, ATP7B, CTR1), dysregulated metallothioneins, changed ceruloplasmin function, and impaired cellular copper delivery. These metal abnormalities directly promote amyloid-beta aggregation, tau phosphorylation, and generation of reactive oxygen species[1][2].
Companies in this space pursue mechanisms including direct copper/zinc modulation at the protein level, metalloprotein targeting, copper transport protein modulators, and approaches that restore proper metal ion distribution in the brain.
| Company | Focus | Mechanism | Stage | Notes |
|---|---|---|---|---|
| Apopharma | Iron/copper chelation | Deferiprone (oral iron chelator) | Research/Preclinical | Primarily PD focus; exploring AD applicability |
| Alterity Therapeutics | Metal-binding protein aggregation | Quinazolinone small molecules | Phase 1 (PD) | Originally developed PBT2 for AD/PD; targets metal-protein interactions |
Copper Transport Protein Modulation: Targeting ATP7A, ATP7B, and CTR1 to normalize copper delivery to neurons and proper cellular distribution.
Metallothionein Modulation: Enhancing metallothionein (MT1, MT2, MT3) function to improve copper and zinc binding, storage, and distribution.
Ceruloplasmin Enhancement: Improving ceruloplasmin function to restore proper copper transport and ferroxidase activity.
Zinc Transporter Targeting: Modulating ZIP (SLC39A) and ZnT (SLC30A) transporter families to normalize brain zinc levels.
Synaptic Zinc Modulation: Addressing zinc dysregulation at synapses where zinc plays critical signaling roles.
Zinc-Aβ Interaction Inhibition: Preventing zinc from accelerating amyloid-beta aggregation.
pGlu-Aβ Reduction: Glutaminyl cyclase inhibition reduces pGlu-modified Aβ with enhanced metal-binding.
TREM2 Agonism: Enhancing microglial metal-handling receptors to improve cellular copper/zinc balance.
Metallochaperone Enhancement: Supporting cellular copper delivery pathways.
Copper plays essential roles in neuronal function, neurotransmitter synthesis, and antioxidant defense:
Zinc is critical for synaptic function and amyloid processing:
The intersection of metal homeostasis and protein pathology:
| Company | Drug | Mechanism | Phase | Indication |
|---|---|---|---|---|
| Aleza Therapeutics | AZT-101 | TREM2 agonist/copper-zinc modulation | Phase IIa | Early AD |
| Vivoryon | Varoglutamstat | QC inhibitor (reduces metal-binding Aβ) | Phase IIb | Early AD |
| T3D Therapeutics | T3D-959 | PPAR δ/γ agonist (metabolic metal modulation) | Phase 2 | AD |
| Apopharma | Deferiprone | Copper/iron chelation | Research | AD |
Copper and zinc in Alzheimer's disease. Progress in Neurobiology. 2021. ↩︎ ↩︎
Metal dyshomeostasis in Alzheimer's disease. Nature Reviews Neurology. 2023. ↩︎ ↩︎
Targeting neuroinflammation in Alzheimer's disease: From mechanisms to clinical trials. Neuron. 2023. ↩︎